CK 0045
Alternative Names: CK-0045Latest Information Update: 02 Aug 2024
At a glance
- Originator Novo Nordisk
- Developer Cytoki Pharma
- Class Anti-inflammatories; Antihyperglycaemics; Interleukins; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Interleukin-22 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
- Preclinical Inflammatory bowel diseases; Type 2 diabetes mellitus
Most Recent Events
- 23 Jul 2024 Preclinical trials in Type 2 diabetes mellitus in Denmark (SC) prior to July 2024 (Cytoki Pharma website; July 2024)
- 23 Jul 2024 Efficacy, adverse event and pharmacokinetics data from the phase I trial in Obesity released by Cytoki Pharma
- 23 Jul 2024 Pharmacodynamics data from the preclinical trial in Obesity and Type 2 diabetes mellitus released by Cytoki Pharma